Emile Voisine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emile Voisine has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Mario Sénéchal
Department of Cardiology Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University Québec City Québec Canada
3 shared publications- Mario Sénéchal
Quebec Heart and Lung Institute, Laval University, Quebec City, QC G1V 4G5, Canada
3 shared publications Alexander Beaulieu-Shearer
Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec, Québec City, Québec, Canada
2 shared publicationsClaudine Laliberté
Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec, Québec City, Québec, Canada
2 shared publicationsDavid Belzile
Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec, Québec City, Québec, Canada
2 shared publicationsFlorence Bernier
Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Québec City, Québec, Canada
2 shared publications
Latest Publications
- Open Access
- 15 March 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (9) , 1217-1223
Cardiac sarcoidosis with extensive and heterogeneous left ventricular FDG uptake in absence of guidelines indication for an implantable defibrillator: Ventricular tachycardia precipitated by immunosuppressive therapy, should we have done differently?
A 40‐year‐old man, newly diagnosed with cardiac sarcoidosis (CS) presented with symptomatic ventricular tachycardia three days after starting steroid‐based immunosuppressive therapy (IT). There was no clear guideline indication for implantable cardioverter‐defibrillator (ICD) before the initiation of IT. Shortly after ICD implantation and the initiation of anti‐arrhythmic drugs, recurring ventricular arrhythmias required titration of the anti‐arrhythmic drug therapy. One‐year follow‐up assessment showed no significant arrhythmias and complete PET scan FDG uptake suppression. This case, along with recent publications, suggests transient pro‐arrhythmic effects of steroids in patients with CS, which are not appropriately addressed in the current guidelines. We believe ICD implantation should be considered in clinically manifest CS before initiating IT, particularly in cases with heterogeneous and/or extensive FDG uptake on PET scans.
- 15 March 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (9) , 1217-1223
Open AccessCardiac sarcoidosis with extensive and heterogeneous left ventricular FDG uptake in absence of guidelines indication for an implantable defibrillator: Ventricular tachycardia precipitated by immunosuppressive therapy, should we have done differently?
A 40‐year‐old man, newly diagnosed with cardiac sarcoidosis (CS) presented with symptomatic ventricular tachycardia three days after starting steroid‐based immunosuppressive therapy (IT). There was no clear guideline indication for implantable cardioverter‐defibrillator (ICD) before the initiation of IT. Shortly after ICD implantation and the initiation of anti‐arrhythmic drugs, recurring ventricular arrhythmias required titration of the anti‐arrhythmic drug therapy. One‐year follow‐up assessment showed no significant arrhythmias and complete PET scan FDG uptake suppression. This case, along with recent publications, suggests transient pro‐arrhythmic effects of steroids in patients with CS, which are not appropriately addressed in the current guidelines. We believe ICD implantation should be considered in clinically manifest CS before initiating IT, particularly in cases with heterogeneous and/or extensive FDG uptake on PET scans.
- 21 August 2021
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 36 (11) , 4440
Response—Letter to the editor "Change in Mitral Regurgitation Severity after Transcatheter Aortic Valve Replacement in Patients with Severe Mitral Regurgitation"
Click on the article title to read more.
- 21 August 2021
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 36 (11) , 4440
Response—Letter to the editor "Change in Mitral Regurgitation Severity after Transcatheter Aortic Valve Replacement in Patients with Severe Mitral Regurgitation"
Click on the article title to read more.
- 17 August 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (11) , 4442
Response—Letter to the Editor JOCS‐LE‐1082
- 17 August 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (11) , 4442
Response—Letter to the Editor JOCS‐LE‐1082
- 23 June 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (9) , 3100-3111
Prognosis of functional mitral regurgitation after aortic valve replacement for pure severe aortic stenosis
Objective Whether patients with severe aortic stenosis (AS) and significant functional mitral regurgitation (MR) should undergo isolated aortic (aortic valve replacement [AVR]) or double aortic-mitral valve procedure (DVP) remains controversial. We sought to determine outcomes of such patients undergoing surgical (surgical aortic valve replacement [SAVR]) and transcatheter AVR (TAVR) or DVP, identify echocardiographic parameters predictive of significant residual MR after isolated AVR, and determine its impact on long-term survival. Methods Data prospectively collected from 736 consecutive patients with severe AS and significant MR undergoing AVR or DVP were retrospectively analyzed. Exclusion of organic MR, other valve diseases and concomitant CABG yielded a final population of 74 patients with significant functional MR (32 TAVR, 23 SAVR, 19 DVP). Demographics, postoperative complications and age-adjusted survival were compared. Echocardiographic predictors of significant residual MR and its impact on survival were analyzed for patients undergoing isolated AVR. Results In the isolated AVR group, MR improvement occurred in 60% of patients and was associated with a significant increase in survival compared to persistence of significant MR (p = .03). Patients with improved MR had significantly greater preoperative left ventricular dilatation (LVEDD: 49 vs. 43 mm, p = .001; LVESD: 35 vs. 29 mm, p = .03; LVEDV: 101 vs. 71 ml, p = .0003; LVESV: 57 vs. 33 ml, p = .002). There was no significant difference in perioperative mortality (5.3 vs. 4.4 vs. 9.4%, p = .85) or age-adjusted long-term survival between isolated AVR and DVP groups (76.3 vs. 84.2% survival at 2-year follow-up, p = .26), or between SAVR, TAVR and DVP groups (78.2 vs. 75.0 vs. 84.2% survival at 2-year follow-up, p = .13). Conclusions After isolated AVR, MR improvement occurs in 60% of patients. It is predicted by greater ventricular dimensions and associated with significantly better long-term survival. Whether a staged approach with transcatheter correction of MR should be considered in patients with significant residual MR following AVR remains undetermined.
- 23 June 2021
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 36 (9) , 3100-3111
Prognosis of functional mitral regurgitation after aortic valve replacement for pure severe aortic stenosis
Objective Whether patients with severe aortic stenosis (AS) and significant functional mitral regurgitation (MR) should undergo isolated aortic (aortic valve replacement [AVR]) or double aortic-mitral valve procedure (DVP) remains controversial. We sought to determine outcomes of such patients undergoing surgical (surgical aortic valve replacement [SAVR]) and transcatheter AVR (TAVR) or DVP, identify echocardiographic parameters predictive of significant residual MR after isolated AVR, and determine its impact on long-term survival. Methods Data prospectively collected from 736 consecutive patients with severe AS and significant MR undergoing AVR or DVP were retrospectively analyzed. Exclusion of organic MR, other valve diseases and concomitant CABG yielded a final population of 74 patients with significant functional MR (32 TAVR, 23 SAVR, 19 DVP). Demographics, postoperative complications and age-adjusted survival were compared. Echocardiographic predictors of significant residual MR and its impact on survival were analyzed for patients undergoing isolated AVR. Results In the isolated AVR group, MR improvement occurred in 60% of patients and was associated with a significant increase in survival compared to persistence of significant MR (p = .03). Patients with improved MR had significantly greater preoperative left ventricular dilatation (LVEDD: 49 vs. 43 mm, p = .001; LVESD: 35 vs. 29 mm, p = .03; LVEDV: 101 vs. 71 ml, p = .0003; LVESV: 57 vs. 33 ml, p = .002). There was no significant difference in perioperative mortality (5.3 vs. 4.4 vs. 9.4%, p = .85) or age-adjusted long-term survival between isolated AVR and DVP groups (76.3 vs. 84.2% survival at 2-year follow-up, p = .26), or between SAVR, TAVR and DVP groups (78.2 vs. 75.0 vs. 84.2% survival at 2-year follow-up, p = .13). Conclusions After isolated AVR, MR improvement occurs in 60% of patients. It is predicted by greater ventricular dimensions and associated with significantly better long-term survival. Whether a staged approach with transcatheter correction of MR should be considered in patients with significant residual MR following AVR remains undetermined.